Mckesson outlines fiscal 2027 adjusted EPS of $45.60-$46.40 while closing $2.25B Precision Medicine Group deal

Open the sourceReported by Seeking Alpha, seekingalpha.com, 5 November 2026

Impact 65 of 100, notable

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Muhabbit only has the headline for this one. The full report is at seekingalpha.com.

Named in this story

McKesson (MCK), Precision Medicine Group

A linked name opens that asset's sentiment page.